Apollo Cancer Centre launches first Robotic and Stereotactic Therapy Education Centre

Published On 2024-06-27 07:00 GMT   |   Update On 2024-06-27 07:01 GMT

Bangalore: Apollo Cancer Centres (ACC), in association with Accuray, a global provider of radiation therapy devices recently announced the launch of India Sub-Continent's first robotic and stereotactic therapy education centre, Robotic & Stereotactic Radiosurgery program.

This initiative will be established at ACC in Chennai and Bangalore, and will provide advanced radiosurgery educational training to radiation oncologists, physicists, radiation therapists, and technologists from India and across the India Sub-continent.

The program includes comprehensive discussions, demonstrations, and hands-on training focusing on robotic and stereotactic radiosurgery. This initiative marks a significant milestone in India’s medical education landscape, making world-class training available locally.

Also Read:Apollo Cancer Centers' Doctors Perform World's first eyebrow keyhole surgery for Brain Tumor

Participants will engage in in-depth discussions, and demonstrations ensuring a robust and practical learning experience.

Mr Dinesh Madhavan, President Group Oncology, and International, Apollo Hospital Enterprises Ltd, said, “In the field of cancer care ground-breaking technologies pave the way for highly personalized and effective treatment. The inception of the Robotic Stereotactic Radiotherapy Program by Apollo Cancer Centres and Accuray will advance training facilities for the ASEAN region. It will help equip oncologists, physicists, and therapists with the critical knowledge and skills needed to leverage the latest in CyberKnife technology. ”

Dr Sridhar PS, Lead- Cyberknife – Robotic Radiosurgery, said, “The launch of the training program at Apollo Cancer Centre is an exceptional opportunity to enhance skills and knowledge in Robotic & Stereotactic Radiotherapy. Since pioneering the Cyberknife Robotic Radio Surgery System in India and a rich experience of over 5000 patients, we will now share the valuable knowledge in the training program. It will enable oncologists in the development of Cancer care through Cyberknife training.”

Ms Suzanne Winter, President & CEO, Accuray, said, “Accuray celebrates the expansion of the CyberKnife® S7™ System to Apollo centers in Chennai and Bangalore, showcasing our enduring collaboration with Apollo Hospitals to enhance cancer care in India. With its unparalleled precision, the CyberKnife S7 System redefines treatment standards, empowering clinicians to optimize outcomes. Additionally, it enables the delivery of high doses of radiation, typically in 1 to 5 sessions for fast and effective treatments, marking a significant advancement in cancer therapy.”

The CyberKnife System is a non-invasive, robotic radiation therapy device designed to treat tumors with high precision and minimal damage to surrounding healthy tissue. It uses advanced imaging and computerized robotics to deliver highly focused beams of radiation, allowing for the treatment of complex and hard-to-reach tumors.

With an aim to provide a world-class comprehensive ‘Educational Center’, the Academia will benefit aspiring CyberKnife clinicians of India and the Subcontinent.

By bringing such a high-caliber educational initiative to India, Apollo Cancer Centres continues to lead the way in medical innovation, dedicated to enhancing the skills of healthcare professionals and ultimately, improving patient outcomes across the country.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News